The properties of the blood-brain barrier serve a vital protective role, but they also keep drugs from reaching the organ. Big pharmaceutical companies have been making deals for technologies that ...

Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a megadeal that signals how aggressively big pharma is now chasing ...

Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases Financing was co-led by EQT Life ...

The highly selective border lining the brain’s vasculature is the Achilles’ heel of any large therapeutic molecule aiming for targets in the brain, anti-Aβ antibodies included. Not only do fewer than ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...